Overview of the Biosimilar Market in Japan 2016: Market Situation, Pipeline, Major Players, and Challenges and Forecasts

Dublin, Oct. 20, 2016 -- Research and Markets has announced the addition of the "The Overview of Biosimilar Market in Japan ver2016" report to their offering.

The reader will understand overall trend of Japanese biosimilar market. The report covers market situation, pipeline, major players, and challenges and forecast of this market.

The market size for generics in 2012 was about 551 billion JPY. This was about 9% of the prescription drugs market as a whole. The generics market is estimated to grow to around 778 billion JPY in 2016.

The market for biosimilars was 4.5 billion JPY in 2012. A total of only three products including human growth hormone and erythropoietin were on the market by 2012. The market is expected to reach over 26 billion JPY by 2016.

Key Topics Covered:

1. Summary

2. Definition of biosimilar

3. Related Pharmaceutical Affairs

4. Market Size

5. Market Trends

6. Biosimilar Sales Items and Main Development Items (As of 2015)

7. Trends for Major Companies

8. Daiichi Sankyo

9. Nichi-Iko

10. Sanwa Kagaku

11. Mochida Pharmaceutical

12. Nippon Kayaku

13. Kissei

14. Boehringer Ingelheim

15. Future Development

16. Challenges and Forecast for Biosimilars

For more information about this report visit http://www.researchandmarkets.com/research/hbs5t6/the_overview_of

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Biosimilars and Biosuperiors